TrialJournal for immunotherapy of cancer2022

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).

Takashi Seto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.